Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Astellas Raises Full-Year Net Income Forecast on Lower Costs

Nov. 1 (Bloomberg) -- Astellas Pharma Inc., Japan’s third-largest drugmaker, raised its full-year profit forecast 4.9 percent, citing lower costs and a one-time gain from selling land.

Net income for the 12 months ending March 31 may total 85 billion yen, compared with an earlier estimate of 81 billion yen, the Tokyo-based company said in a statement today. Costs for research and development may be 6 billion yen less than previously estimated, Astellas said. Sales and administrative costs may also be less than Astellas predicted earlier, the company said.

Link to Company News:{4503 JP <Equity> CN <GO>}

To contact the reporter on this story: Kanoko Matsuyama in Tokyo at

To contact the editor responsible for this story: Jason Gale at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.